|
Advertisement
|
 |
|
|
| Newswire |
|
 |
Walgreens to Acquire Duane Reade
Deerfield, IL — Walgreens has announced that it will purchase the entire 257-store Duane Reed chain, all located in the New York City area. The deal, which is contingent upon regulatory approvals, is valued at $1.08 billion. Duane Reade will continue to operate under its brand name after the transaction closes by the end of the summer. Walgreens said that it expects to retain Duane Reade's store, pharmacy, and distribution-center employees and many members of Duane Reade's senior management team. |
|
|
More McNeil OTCs Recalled
Fort Washington, PA — Some 500 lots of OTC drugs made by McNeil Consumer Healthcare were recalled following an earlier recall of Tylenol Arthritis Pain Caplet 100-count bottles that started in November, the FDA said. The latest recalls, also arising from consumer complaints of nausea, vomiting, stomach pain, and diarrhea, include lots of various adult and children's Tylenol products, Motrin IB tablets and caplets, Benadryl Allergy tablets, Rolaids antacid tablets, Simply Sleep mini-caplets, and St. Joseph chewable and safety-coated aspirin. Not all lots have been linked to complaints of unusual odors, but they all have the potential to be affected, according to McNeil. |
|
|
Jury Awards More Than $25 Million Over Acne Drug
Atlantic City, NJ — A New Jersey Superior Court jury found that Hoffmann-La Roche failed to adequately warn Andrew McCarrell's prescribing physician of possible long-term inflammatory bowel disease (IBD) associated with the acne drug Accutane, awarding McCarrell $25.16 million in compensatory damages. McCarrell, prescribed the powerful acne medication at the age of 23, then developed a severe case of IBD and later had his colon removed. The decision follows a string of plaintiffs' wins against Roche over charges that Accutane was a cause of severe bowel maladies, chronic bowel disease, and, in some cases, removal of all or part of plaintiffs' colons and intestines. |
|
|
FDA Approves Statin for Primary CVD Prevention
Silver Spring, MD — The FDA has approved rosuvastatin (Crestor) for the primary prevention of cardiovascular disease (CVD), making it the first statin to receive this indication. The new labeling is also the first to include an indication based on the inflammatory biomarker C-reactive protein (CRP). The new indication would be for men aged 50 or older and women aged 60 or older who have a fasting LDL of less than 130 mg/dL, a highly sensitive CRP of 2.0 mg/L or greater, triglycerides of less than 500 mg/dL, and no prior history of heart attack or stroke or risk of coronary heart disease. |
|
|